The Good, the Bad and the Ugly: Epigenetic Mechanisms in Glioblastoma

Overview

Journal Mol Aspects Med

Specialties Biochemistry
Molecular Biology

Date 2012 Jul 10

PMID 22771539

Citations 27

Authors

Helena Caren

Steven M Pollard

Stephan Beck

Affiliations

Soon will be listed here.

Abstract

Cell type-specific patterns of gene expression reflect epigenetic changes imposed through a particular developmental lineage as well as those triggered by environmental cues within adult tissues. There is great interest in elucidating the molecular basis and functional importance of epigenetic mechanisms in both normal physiology and disease - particularly in cancer, where abnormal '-omic' states are often observed. In this article we review recent progress in studies of epigenetic mechanisms in the most common primary adult brain cancer, glioblastoma multiforme. Three distinct areas are discussed. First, the evidence in support of ongoing 'normal' epigenetic processes associated with differentiation - as predicted by 'cancer stem cell' models of the disease. Second, identification of site-specific and global epigenetic abnormalities. Third, genetic disruptions directly within the core epigenetic machinery, exemplified by the recently identified mutations within isocitrate dehydrogenase genes IDH1/2 and variant histone genes H3.3/H3F3A. These constitute the 'good, the bad and the ugly' of epigenetic mechanisms in cancer.

Citing Articles

Genomic, epigenomic and transcriptomic landscape of glioblastoma.

Dakal T, Kakde G, Maurya P Metab Brain Dis. 2024; 39(8):1591-1611.

PMID: 39180605 DOI: 10.1007/s11011-024-01414-8.

Unravelling the mosaic: Epigenetic diversity in glioblastoma.

Lucchini S, Constantinou M, Marino S Mol Oncol. 2024; 18(12):2871-2889.

PMID: 39148319 PMC: 11619803. DOI: 10.1002/1878-0261.13706.

Galectins as Emerging Glyco-Checkpoints and Therapeutic Targets in Glioblastoma.

Videla-Richardson G, Morris-Hanon O, Torres N, Esquivel M, Vera M, Ripari L Int J Mol Sci. 2022; 23(1).

PMID: 35008740 PMC: 8745137. DOI: 10.3390/ijms23010316.

Long non-coding RNAs in brain tumors.

Katsushima K, Jallo G, Eberhart C, Perera R NAR Cancer. 2021; 3(1):zcaa041.

PMID: 34316694 PMC: 8210177. DOI: 10.1093/narcan/zcaa041.

Targeting CDK9 for the Treatment of Glioblastoma.

Ranjan A, Pang Y, Butler M, Merchant M, Kim O, Yu G Cancers (Basel). 2021; 13(12).

PMID: 34207158 PMC: 8234280. DOI: 10.3390/cancers13123039.

References

Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J . Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet. 2007; 39(2):232-6. DOI: 10.1038/ng1950. View

Reya T, Morrison S, Clarke M, Weissman I . Stem cells, cancer, and cancer stem cells. Nature. 2001; 414(6859):105-11. DOI: 10.1038/35102167. View

Oshimo Y, Nakayama H, Ito R, Kitadai Y, Yoshida K, Chayama K . Promoter methylation of cyclin D2 gene in gastric carcinoma. Int J Oncol. 2003; 23(6):1663-70. View

Mueller W, Nutt C, Ehrich M, Riemenschneider M, Deimling A, van den Boom D . Downregulation of RUNX3 and TES by hypermethylation in glioblastoma. Oncogene. 2006; 26(4):583-93. DOI: 10.1038/sj.onc.1209805. View

Jones P, Baylin S . The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6):415-28. DOI: 10.1038/nrg816. View

Horiguchi K, Tomizawa Y, Tosaka M, Ishiuchi S, Kurihara H, Mori M . Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors. Oncogene. 2003; 22(49):7862-5. DOI: 10.1038/sj.onc.1207082. View

Saito Y, Jones P . Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle. 2006; 5(19):2220-2. DOI: 10.4161/cc.5.19.3340. View

Jacque C, Vinner C, Kujas M, Raoul M, RACADOT J, Baumann N . Determination of glial fibrillary acidic protein (GFAP) in human brain tumors. J Neurol Sci. 1978; 35(1):147-55. DOI: 10.1016/0022-510x(78)90107-7. View

Blanc J, Wager M, Guilhot J, Kusy S, Bataille B, Chantereau T . Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neurooncol. 2004; 68(3):275-83. DOI: 10.1023/b:neon.0000033385.37098.85. View

10.

Toyota M, Ahuja N, Suzuki H, Itoh F, Imai K, Baylin S . Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res. 1999; 59(21):5438-42. View

11.

Liu B, Cheng J, Zhang X, Wang R, Zhang W, Lin H . Global histone modification patterns as prognostic markers to classify glioma patients. Cancer Epidemiol Biomarkers Prev. 2010; 19(11):2888-96. DOI: 10.1158/1055-9965.EPI-10-0454. View

12.

Xie W, Barr C, Kim A, Yue F, Lee A, Eubanks J . Base-resolution analyses of sequence and parent-of-origin dependent DNA methylation in the mouse genome. Cell. 2012; 148(4):816-31. PMC: 3343639. DOI: 10.1016/j.cell.2011.12.035. View

13.

Gu T, Guo F, Yang H, Wu H, Xu G, Liu W . The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature. 2011; 477(7366):606-10. DOI: 10.1038/nature10443. View

14.

Kriaucionis S, Heintz N . The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science. 2009; 324(5929):929-30. PMC: 3263819. DOI: 10.1126/science.1169786. View

15.

Pastor W, Pape U, Huang Y, Henderson H, Lister R, Ko M . Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature. 2011; 473(7347):394-7. PMC: 3124347. DOI: 10.1038/nature10102. View

16.

Fraga M, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G . Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005; 37(4):391-400. DOI: 10.1038/ng1531. View

17.

Zhou L, Cheng X, Connolly B, Dickman M, Hurd P, Hornby D . Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol. 2002; 321(4):591-9. PMC: 2713825. DOI: 10.1016/s0022-2836(02)00676-9. View

18.

Jenuwein T, Allis C . Translating the histone code. Science. 2001; 293(5532):1074-80. DOI: 10.1126/science.1063127. View

19.

Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin N . Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006; 9(5):391-403. DOI: 10.1016/j.ccr.2006.03.030. View

20.

Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M . Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110. PMC: 2818769. DOI: 10.1016/j.ccr.2009.12.020. View